Dr. Habil Khorakiwala founded Wockhardt in 1967. He has gone on to build a multinational enterprise active in the fields of pharmaceuticals, biotechnology and hospitals and created one of India’s leading healthcare businesses.
As well as being a highly successful entrepreneur he has held many senior positions as an industry representative and is highly respected in India and overseas. As a former president of FICCI (Federation of Indian Chambers of Commerce & Industry) Dr. Khorakiwala represented India’s business interests to many presidents, prime ministers and heads-of-state.
He is currently the Chairman of the Board of Governors at the Centre for Organisation & Development in Hyderabad, a non-profit scientific and industrial research organisation, and a recognised doctoral research centre.
A Harvard alumni, Dr. Habil Khorakiwala is a member of the World Economic Forum and was a distinguished speaker at its 2008 Davos meeting. A graduate of Purdue University in the US, in 2010 he was awarded an honorary doctorate by his alma mater.
He has served as the Honorary Consul General of Sweden in Mumbai.
Dr. Murtaza Khorakiwala graduated in medicine from GS Medical College, Mumbai. He holds an MBA degree from the University of Illinois, USA.
Dr. Khorakiwala is the Managing Director of Wockhardt Ltd. since April 2009. His young and dynamic leadership has become an ideal springboard for various corporate initiatives in creating a New Wockhardt.
A member of the executive committee of the Indian Pharmaceutical Association (IPA), he was the Past Chairman of the Marketing Committee of the Bombay Management Association.
Mr. Huzaifa Khorakiwala is a Bachelor of Commerce graduate from Mumbai University. He holds a Masters degree in Business Management from Yale University School of Management, USA.He joined the company in July 1996 and over the years has run various Wockhardt businesses and served in Corporate Administration.
Dr. Huzaifa Khorakiwala devotes a significant part of his time to Wockhardt’s corporate social responsibility activities. He serves as CEO of the Wockhardt Foundation.
Singh became a part of Wockhardt during the acquisition of Merind in 1998 and was actively involved in the post-acquisition, integration and rationalisation with the parent Company.
In 2002, Sirjiwan was appointed as General Manager, Contract Manufacturing and in 2003; he was posted in UK to handle the integration activities of the newly acquired CP Pharmaceuticals. Thereafter, he played a key role in restructuring the product portfolio and rejuvenated the business performance in UK.
Recently, Sirjiwan was given additional responsibility of overseeing the Ireland operations of Pinewood. As Managing Director of Wockhardt UK and Pinewood, he is responsible for growing the business in these regions through strategic implementations across the sales, marketing, manufacturing and operation functions.
Sirjiwan Singh is all poised and geared to build a robust business for these regions by exploring alliances and tapping new business opportunities.
Sunil Khera joined Wockhardt in January 2006 as President - Domestic Business and later was entrusted with an additional responsibility of handling the Emerging Markets and RoW business.
He is currently focusing his full attention in managing the Americas business (includes the US, Canada & Lat-Am countries).
Ajay Sahni joined Wockhardt in February 2007 and brings with him around 23 years of pharmaceutical work experience in the areas of Business Development (M&A), Strategic Planning and Regional Finance Management.
He is currently managing the European hub office in Switzerland and also overlooks the Negma operations in France.
With an experience spanning multi-cultural environments in the US, Europe and SE Asia, Ajay is adept at bridging language and cultures in alignment with the Company ethos.
Sanjeev Mehta has being with Wockhardt for the past 25 years and has grown along with the organisation.
His efforts have fructified in creating an end-to-end global supply chain for Wockhardt, which is a benchmark in the pharma industry. He has successfully implemented SAP in supply chain, which tracks on-line sales, service levels and product availability. He has also played a pivotal role in integrating the supply chain network of acquired companies seamlessly with the parent company.
Sanjeev also manages the India Generic and API businesses for Wockhardt.
Dr. Ajaz Hussain provides leadership for the Biotechnology and Clinical functions at Wockhardt. He also broadly contributes his scientific expertise to improve rigor and sufficiency of scientific evidence to obtain successful regulatory approval of complex product applications.
Dr. Hussain trained at the Bombay College of Pharmacy (B.Pharm.) and at the University of Cincinnati (Ph.D.). He is a Fellow of the American Association of Pharmaceutical Scientists and the Swiss Society for Pharmaceutical Sciences. He brings to Wockhardt over 25 years of professional experience including regulatory experience from his leadership role at the US FDA.
Dr. Yatendra Kumar joined Wockhardt in April 2005 and has more than 26 years of research experience.
At Wockhardt, he provides leadership and development strategies for several departments related with process and formulation R&D.
Nalin Garg joined Wockhardt in July 2011. With a varied industry experience of around 20 years in human resources, Nalin is spearheading Wockhardt’s critical asset management – its People.
He is also actively involved in talent development, acquisition and employee engagement.
Venkat Iyer joined Wockhardt in November 2011. He has a Masters in Business Administration from South Gujarat University and a Masters in Information Systems from University of Bridgeport (USA).
Venkat has a clear mandate to leverage Medical IT Technology as a distinctive differentiator for Wockhardt. All IT teams across Wockhardt businesses around the globe report to Venkat.
Giri joined Wockhardt in November 2010. He is well endowed with over 24 years of experience working across Asia and Europe in Finance, M&A and Strategy.
Giri leads the entire finance function for the Wockhardt group.